ArticleJournal of cheminformatics2026
ADMET property prediction and toxicity profiling of CDK2 inhibitors: a practical cheminformatics tutorial using ADMET-AI 2.0 and RDKit.
Article in Journal of cheminformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) prediction plays a central role in modern computer-aided drug discovery by enabling early evaluation of pharmacokinetic behaviour and safety liabilities. This tutorial presents a reproducible computational workflow for large-scale ADMET profiling using ADMET-AI 2.0, a graph neural network-based prediction platform, applied to 200 cyclin-dependent kinase 2 (CDK2) inhibitors curated from ChEMBL release 35. Implemented within an annotated Jupyter notebook, the workflow integrates cheminformatics preprocessing, physicochemical property analysis, drug-likeness evaluation, structural alert screening, absorption and distribution profiling, CYP450-mediated metabolism prediction, excretion assessment, toxicity evaluation, Tox21 pathway analysis, DrugBank percentile benchmarking, and composite multi-parameter optimisation scoring. A total of 104 ADMET-related outputs were generated per compound, including 52 predictive endpoints and 52 corresponding DrugBank approved-drug percentile rankings. The 200 curated CDK2 inhibitors exhibited 100% Lipinski Ro5 compliance, 38.5% predicted CYP3A4 inhibition, 73.5% predicted hERG liability, and 99.5% predicted DILI risk, with a mean composite ADMET score of 0.46 and a mean traffic light green flag count of 9.5/13. The workflow provides an accessible and FAIR-compliant framework for ADMET analysis, cheminformatics education, and reproducible computational drug discovery.Scientific contributionThis work contributes a structured educational framework for teaching and implementing computational ADMET analysis in modern drug discovery. To be explicit about the nature of this contribution: the novelty is pedagogical and integrative rather than methodological, no new prediction model, algorithm, or endpoint is introduced. The study demonstrates how an existing graph neural network-based prediction model (ADMET-AI) can be integrated with open-source cheminformatics workflows to support interpretable and reproducible pharmacokinetic assessment. Beyond endpoint prediction, the tutorial emphasises practical data handling, workflow automation, compound prioritisation, and transparent result interpretation within a Jupyter notebook environment. The inclusion of DrugBank percentile benchmarking, traffic-light visualisation, and composite scoring strategies provides learners and researchers with practical, worked examples of established multi-parameter decision-making approaches during lead optimisation, rather than new decision frameworks in their own right. By combining methodological clarity with FAIR and reproducible research principles, the workflow serves as a scalable resource for cheminformatics education, computational pharmacology training, and ADMET-guided drug development studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.